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INVESTIGATION
Mono and Dual Cofactor Dependence of Human
Cystathionine b-Synthase Enzyme Variants
In Vivo and In Vitro
Dago Dimster-Denk,1 Katherine W. Tripp,1 Nicholas J. Marini, Susan Marqusee, and Jasper Rine2
The California Institute for Quantitative Biosciences, Department of Molecular and Cellular Biology, University of
California, Berkeley, California 94720
ABSTRACT Any two individuals differ from each other by an average of 3 million single-nucleotide
polymorphisms. Some polymorphisms have a functional impact on cofactor-using enzymes and therefore
represent points of possible therapeutic intervention through elevated-cofactor remediation. Because most
known disease-causing mutations affect protein stability, we evaluated how the in vivo impact caused by
single amino acid substitutions in a prototypical enzyme of this type compared with physical characteristics
of the variant enzymes in vitro. We focused on cystathionine b-synthase (CBS) because of its clinical
relevance in homocysteine metabolism and because some variants of the enzyme are clinically responsive
to increased levels of its B6 cofactor. Single amino-acid substitutions throughout the CBS protein caused
reduced function in vivo, and a subset of these altered sensitivity to limiting B6-cofactor. Some of these B6-
sensitive substitutions also had altered sensitivity to limiting heme, another CBS cofactor. Limiting heme
resulted in reduced incorporation of heme into these variants, and subsequently increased protease sen-
sitivity of the enzyme in vitro. We hypothesize that these alleles caused a modest, yet signiﬁcant, destabi-
lization of the native state of the protein, and that the functional impact of the amino acid substitutions
caused by these alleles can be inﬂuenced by cofactor(s) even when the affected amino acid is distant from
the cofactor binding site.
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The interpretation of human genome variation is a deﬁning challenge
in human biology for the foreseeable future. The unprecedented in-
crease in both total sequence information and in the number of new
gene variants has created a critical bottleneck in the ability to interpret
the impact of the genetic variants in an individual. Clearly, advances in
interpretation are crucial to realize the potential of personalized med-
icine. As one measure of the magnitude of the challenge, any two
unrelated humans differ by an average of 3 million single-nucleotide
polymorphisms (SNPs). Among the SNPs in an individual, a current
estimate is that 10,000 cause a change in the sequence of a protein
(Abecasis et al. 2012; Tennessen et al. 2012). Moreover, each individ-
ual has changes in genes that have been implicated in human disease
(Levy et al. 2007). The pace of SNP discovery far outpaces the speed at
which polymorphisms are experimentally evaluated. For mutations
that cause disease with Mendelian inheritance due to a single amino
acid substitution, the vast majority is believed to decrease the stability
(free energy of folding) of the protein, leading to partial or global un-
folding and either aggregation or degradation (Yue et al. 2005). If this
observation were to apply broadly to nonsynonymous SNPs, then ro-
bustly predictive calculations of the energetic effects caused by these
mutations could, in principle, make a valuable contribution to genome
sequence interpretation. Well-characterized sets of variant forms of mul-
tiple proteins are needed to help drive the development of such methods.
A particular subclass of sequence variants of great interest and
potential importance is the set of mutations whose deleterious effects
on proteins are readily remediable by simple means. The prototype
for such mutations were ﬁrst highlighted in bacterial genetic studies
of mutations in genes encoding certain vitamin-dependent enzymes
that can be suppressed by increased levels of their cognate vitamins
(Guirard et al. 1971; Ames et al. 2002). In addition, some human
mutations cause clinical phenotypes sensitive to remediation by
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increased vitamin dosages. We hypothesize that vitamin remediation
occurs when a variant enzyme that has lost a crucial amount of free
energy of folding can be compensated by the free energy of binding
with the vitamin. In this case, the vitamin acts as a chemical splint, with
the ligand-binding energy shifting the folding equilibrium and thereby
making up for the partial loss of free energy caused by the mutation.
Such variant proteins could be either dysfunctional, marginally func-
tional, or substantially functional depending upon cofactor availability.
In the human MTHFR gene, the majority of nonsynonymous
changes in this enzyme’s catalytic domain, found in a survey of non-
clinical samples, have deleterious effects on the enzyme (Marini et al.
2008). Moreover, for this enzyme, which participates in folate-driven,
one-carbon metabolism, the deleterious impact of most such genetic
substitutions can be suppressed by simply increasing the level of folate
available to the cell. There is no crystal structure available for human
MTHFR, thereby precluding structure-based approaches to assess the
impact of these mutations, although phylogenetic approaches are
promising (Marini et al. 2010).
In the present study we turned to human cystathionine b-synthase
(CBS), a vitamin-dependent enzyme whose structure is known, to
explore the concept of cofactor remediation more deeply to determine
its prevalence, and whether there are structural principles that can be
illuminated with such alleles. In addition, well-characterized sets of alleles
affecting a protein can serve as a test-bed for efforts such as the Critical
Assessment of Genome Information (https://genomeinterpretation.org).
CBS catalyzes the ﬁrst step of cysteine biosynthesis via the trans-
sulfuration pathway, which consumes homocysteine produced from
methionine metabolism. Human CBS requires two cofactors for func-
tion: vitamin B6 and heme. There are several biological forms of
vitamin B6. The soluble form in vitamin supplements is pyridoxine,
whereas the active form directly involved in CBS function is pyridoxal
59-phospate (PLP). Homocystinuria due to CBS deﬁciency (OMIM
236200) is a recessive inborn-error of sulfur-amino acid metabolism,
resulting in increased levels of homocysteine in the urine. More than
140 different disease-associated mutations have been identiﬁed in the
CBS gene (Kraus et al. 1999, 2013). Several alleles encode proteins that
are clearly pyridoxine remediable: A114V (pyridoxine Km variant),
R266K, R369H, K384E, L539S, and the common I278T variant.
The choice of a B6-dependent enzyme allowed us to test the
generality of the observations from our studies of MTHFR variants
and their responses to folate supplementation. The rationale for the
selection of CBS was several-fold: (1) an in vivo assay for CBS activity
and vitamin-responsiveness is established (Kim et al. 1997; Kruger
and Cox 1994, 1995; Mayﬁeld et al. 2012); (2) the literature on CBS
mutations and disease establish this enzyme as metabolically signiﬁ-
cant (Meier et al. 2003); (3) clinically relevant vitamin B6-responsive
variants provide a benchmark for validation; and (4) the crystal struc-
ture allows for structural-based computational predictions of func-
tional impact, including those based upon calculated free-energy-of
folding changes (Meier et al. 2001). Clinically associated variants are
inherently biased toward dysfunction. Therefore, for this study we
focused our analysis on a set of designed variants with differing co-
factor responses and examined possible conformational changes by
in vitro measurements of thermolysin sensitivity, as recently demon-
strated for studies of CBS (Hnizda et al. 2012a, 2010).
MATERIALS AND METHODS
Plasmids
The plasmid pHUCBS was the kind gift of Warren Kruger (Kruger
and Cox 1995). This plasmid contains the human CBS cDNA (mRNA
reference sequence NM_000071, protein reference sequence NP_000062)
and served as the source of the CBS coding region for all subsequent
plasmid constructions. Polymerase chain reaction was used to amplify
the CBS coding region and subclone the fragment into both a bacterial
expression vector (2C-T, see Protein expression and puriﬁcation below)
as well as a yeast expression vector containing the TEF1 promoter and
CYC1 terminator (p416-TEF; Mumberg et al. 1995). A derivative of
this plasmid placed the hemagglutinin A epitope tag at the 39-end of
the CBS coding region (pJR2858). Site-directed CBS variants were
constructed using the QuickChange II Kit from Agilent (Santa Clara,
CA). Random variant libraries were created using the Diversity PCR
Random Mutagenesis Kit from Clontech (Mountain View, CA) and
cloned into yeast expression vectors by cotransformation with gapped
vector directly into yeast, allowing homologous recombination to con-
struct the expression plasmids. Plasmids were rescued from yeast into
Escherichia coli and sequenced. All mutations were constructed in the
CBS clone containing the hemagglutinin A epitope tag.
For all variant constructs, the entire CBS coding region was sequenced
to ensure that a single amino acid change had been created. Each
sequence-conﬁrmed variant allele was then retransformed into yeast,
and these transformants used for all subsequent analyses of phenotype
and in vivo properties.
Strains
A haploid Saccharomyces cerevisiae strain containing a complete de-
letion of the gene CYS4, encoding yeast cystathionine b-synthase, was
obtained from the yeast knockout collection (Invitrogen), and served as
the parent for all yeast strains used in this study (MATa cys4::KanMX
his3D1 leu2D0 lys2D0 ura3D0). A hem1D strain, deﬁcient in d-amino-
levulinate synthase, was created by the direct transformation of the
cys4D parent with a hem1::LEU2 construct. Expression plasmids car-
rying the human CBS major allele, or variants, were transformed into
this strain by selecting for uracil prototrophy (Ito et al. 1983).
Growth conditions
We adopted the strategy of Kruger et al. for the implementation of an
in vivo CBS assay (Kim et al. 1997; Kruger and Cox 1994, 1995) and
was essentially as described previously (Mayﬁeld et al. 2012). In sum-
mary, plasmid-bearing strains were maintained on synthetic complete
medium lacking uracil and containing glutathione (GSH), a tripeptide
used as a source of cysteine to alleviate the need for functional CBS.
Human CBS function was assayed based upon the growth of cys4D
yeast strains in liquid and on solid minimal medium containing Yeast
Nitrogen Base without vitamins (Qbiogene, Calsbad, CA) or GSH.
Although these strains had wild-type versions of allMET genes, growth
in minimal media also required the addition of methionine, presum-
ably to augment a limiting intracellular concentration of homocysteine
for the human enzyme. All vitamins except B6 (pyridoxine) were added
back individually to levels present in standard medium. Pyridoxine was
then added back at a range of concentrations, the “high” dose was 400
ng/mL, the concentration of pyridoxine present in standard medium.
Intermediate and low doses of pyridoxine were titrated in starting at
4 ng/mL, a concentration slightly less than that required to achieve
maximal growth. Note that even though S. cerevisiae requires PLP for
growth and makes its own PLP, the level of PLP in wild-type yeast is
not sufﬁcient to satisfy the PLP requirement for human CBS when
complementing the yeast cys4 mutation.
For growth-rate measurements, strains containing CBS mutations
were pregrown in minimal medium containing GSH to early stationary
phase at 30. Cells were diluted 1:200 in fresh medium lacking GSH,
but with varying amounts of pyridoxine (starting cell densities were
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n Table 1 CBS Protein Variants Constructed and Analyzed
Plasmid
(pJR #)
Nucleotide
Mutation(s)
Substituted
Residue Rosetta (DDG)
Phenotypic
Category 400 ng/mL B6 4 ng/mL B6 2 ng/mL B6 1 ng/mL B6
2985 194, A/T H65L 1.2 Nonfunctional 0 n/d n/d n/d
2993 424, AT/GC I142A 3.7 Nonfunctional 0 n/d n/d n/d
2994 425, T/A I142N 9.7 Nonfunctional 0 n/d n/d n/d
2996 460, CT/GC L154A 1.8 Nonfunctional 0 n/d n/d n/d
2997 461, T/C L154P 6.7 Nonfunctional 0 n/d n/d n/d
2998 529, A/G K177E 1.2 Nonfunctional 0 n/d n/d n/d
3001 566, T/C V189A 3.1 Nonfunctional 0 n/d n/d n/d
3002 620, C/G A207G 2.0 Nonfunctional 0 n/d n/d n/d
3003 629, T/A L210Q 4.2 Nonfunctional 0 n/d n/d n/d
3005 659, T/G L220R 14.4 Nonfunctional 0 n/d n/d n/d
3007 684, C/A N228K 5.5 Nonfunctional 0 n/d n/d n/d
3008 718, AT/GC I240A 2.1 Nonfunctional 0 n/d n/d n/d
3012 755, T/C V252A 2.6 Nonfunctional 0 n/d n/d n/d
3013 772, G/C G258R 13.7 Nonfunctional 0 n/d n/d n/d
3018 829, AT/CC I277P 5.1 Nonfunctional 0 n/d n/d n/d
3023 967, T/G W323G 6.3 Nonfunctional 0 n/d n/d n/d
3035 1153, TTC/CAA F385Q 5.0 Nonfunctional 0 n/d n/d n/d
3038 1268, T/C L423P n/a Nonfunctional 0 n/d n/d n/d
3040 1370, G/A G457E n/a Nonfunctional 0 n/d n/d n/d
2988 353, T/G V118G 1.9 Sensitive 0.91 6 0.04 0.81 6 0.25 0.49 6 0.23  0.39 6 0.07 
2991 379, A/G I127V 1.5 Sensitive 1.22 6 0.11 1.25 6 0.07  1.35 6 0.15 0.97 6 0.08
2995 424, A/G I142V 1.3 Sensitive 0.66 6 0.03  0.68 6 0.07  0.53 6 0.07 0.38 6 0.10
2999 541, CT/GC L181A 3.1 Sensitive 0.92 6 0.23 0.91 6 0.12 0.56 6 0.11 0.34 6 0.22 
3000 562, A/G I188V 1.0 Sensitive 1.19 6 0.23 1.41 6 0.38 1.42 6 0.53 1.93 6 0.64 
3006 674, A/G N225S 1.4 Sensitive 0.71 6 0.10  0.62 6 0.11  0.35 6 0.09  0.36 6 0.07 
3015 799, A/G K267E 0.9 Sensitive 0.68 6 0.38 0.67 6 0.39 0.47 6 0.28  0.26 6 0.15 
3020 856, AT/GC I286A 1.1 Sensitive 0.52 6 0.10 0.43 6 0.05  0.18 6 0.05  0.13 6 0.11 
3021 877, C/G L293V 1.1 Sensitive 0.57 6 0.08 0.50 6 0.05  0.17 6 0.04  0.25 6 0.06 
3024 1012, CT/GC L338A 1.7 Sensitive 0.98 6 0.11 0.93 6 0.17 0.77 6 0.13  0.74 6 0.14
3026 1034, T/C L345P 21.2 Sensitive 0.57 6 0.04  0.49 6 0.07  0.16 6 0.03  0.20 6 0.14 
3027 1061, T/G V354G 7.5 Sensitive 0.67 6 0.09  0.72 6 0.05  0.48 6 0.09  0.54 6 0.10 
3031 1112, T/C V371A 2.7 Sensitive 1.15 6 0.29 1.15 6 0.37 1.32 6 0.20  1.95 6 0.54
3036 1153, T/C F385L 5.5 Sensitive 0.85 6 0.15 0.72 6 0.05  0.37 6 0.07  0.37 6 0.03 
2986 250, A/G I84V 1.0 Benign 0.99 6 0.05 1.10 6 0.28 1.13 6 0.24 1.31 6 0.34
2990 370, CT/GC L124A 2.3 Benign 0.83 6 0.06 1.00 6 0.06 0.97 6 0.07 1.12 6 0.11
2989 370, C/G L124V 2.1 Benign 0.76 6 0.16 1.10 6 0.18 1.09 6 0.10 1.62 6 0.45
2992 418, G/A D140N 3.0 Benign 1.13 6 0.28 0.93 6 0.11 0.86 6 0.08 0.71 6 0.07
3004 640, A/G I214V 1.1 Benign 0.89 6 0.18 1.16 6 0.19 1.07 6 0.17 1.11 6 0.08
3009 718, A/G I240V 1.0 Benign 0.90 6 0.24 1.14 6 0.21 0.90 6 0.05 1.02 6 0.33
3010 721, C/G L241V 1.4 Benign 1.01 6 0.13 1.03 6 0.19 0.91 6 0.19 0.92 6 0.41
3011 742, CT/GC L248A 1.2 Benign 0.81 6 0.08 0.84 6 0.11 0.73 6 0.14 0.71 6 0.08
3014 791, T/C I264T 3.3 Benign 1.12 6 0.33 1.13 6 0.20 1.05 6 0.33 1.08 6 0.31
3016 800, A/T K267M 21.8 Benign 1.02 6 0.18 1.07 6 0.15 1.10 6 0.21 1.15 6 0.18
3017 811, A/G K271E 0.4 Benign 0.87 6 0.18 0.89 6 0.28 0.80 6 0.20 0.87 6 0.31
3019 839, T/C V280A 2.5 Benign 1.10 6 0.30 1.12 6 0.27 1.13 6 0.23 1.41 6 0.21
3022 931, A/G I311V 0.7 Benign 1.03 6 0.15 1.33 6 0.50 1.12 6 0.44 1.41 6 0.75
3025 1023, A/T Q341H 22.5 Benign 1.09 6 0.23 0.85 6 0.20 0.86 6 0.19 0.86 6 0.10
3028 1067, T/C V356A 1.3 Benign 0.98 6 0.12 1.04 6 0.06 0.94 6 0.00 0.92 6 0.08
3029 1070, C/G A357G 1.6 Benign 1.09 6 0.16 1.17 6 0.23 0.99 6 0.23 0.77 6 0.19
3030 1073, T/C V358A 1.6 Benign 0.92 6 0.10 0.90 6 0.05 0.87 6 0.14 0.73 6 0.08
3032 1115, T/C V372A 2.7 Benign 0.75 6 0.39 0.85 6 0.48 0.68 6 0.38 0.68 6 0.37
3033 1120, CT/GC L374A 2.3 Benign 1.09 6 0.10 1.06 6 0.20 1.17 6 0.24 1.28 6 0.22
3034 1147, A/T T383S 1.1 Benign 0.95 6 0.15 0.87 6 0.14 0.70 6 0.10 0.83 6 0.22
3037 1223, G/T W408L n/a Benign 1.04 6 0.03 1.13 6 0.17 1.19 6 0.16 1.08 6 0.10
3039 1298, A/T H433L n/a Benign 0.98 6 0.22 0.93 6 0.30 0.83 6 0.21 0.72 6 0.13
3041 1468, A/C I490L n/a Benign 0.86 6 0.49 0.74 6 0.42 0.74 6 0.43 0.87 6 0.49
3042 1646, A/G D549G n/a Benign 0.95 6 0.13 0.80 6 0.11 0.69 6 0.10 0.65 6 0.12
3043 1675, T/C Y559H n/a Benign 1.36 6 0.10 1.18 6 0.32 1.15 6 0.35 1.07 6 0.37
The 58 single amino-acid substitutions constructed within the human CBS coding region are listed. The engineered nucleotide change and the resulting change in
amino acid residue are shown (reference sequence NM_000071). The calculated change in free energy based on the Rosetta prediction algorithm for each
substitution is also listed (DDG, kcal/mol), with the exception of seven substitutions located in the N-terminal portion of the protein that is not part of the structure and
therefore no predictions were available (indicated as n/a). All of the protein variants were assigned to one of three phenotypic categories based on empirical
measurements of growth: benign, sensitive, or nonfunctional. The relative growth rates of yeast containing 39 single-amino-acid human CBS substitutions with some
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OD595 = 0.01 in a volume of 150 mL). Cell number was measured every
30 min for 72296 hr in a Tecan GENios plate reader at 27228
without shaking. For growth-rate calculations, raw OD595 values were
normalized to an endpoint read after the cells were resuspended. The
normalized OD595 values were then log10 transformed, and the growth
rate determined from the slopes calculated between two ﬁxed cell
densities (0.0520.1 for HEM1 cells, and 0.120.2 for hem1D cells).
A plate normalization factor was applied to account for plate-to-plate
variations, and the variant growth rates expressed as a ratio relative to
the growth rate resulting from the major allele.
Thermodynamic predictions of the impact of single
amino acid variations
The Rosetta computational model for predicting the structural effect
of single amino acid substitutions involves a process whereby the side-
chain rotamers are sampled while keeping the protein backbone ﬁxed
(Bonneau et al. 2002; Das and Baker 2008; Kellogg et al. 2011; Rohl
et al. 2004). The calculated energy function consists of an all-atom
description including physical and statistical terms. Results from ear-
lier work established a benchmark to assess the predictions from this
project. In that work, 985 point mutations in 77 different protein
structures were examined. The Pearson correlation coefﬁcient between
the predicted and the experimental assessment of function was 0.64
for the entire set (D. Baker and P. Bradley, unpublished data).
Protein expression and puriﬁcation
A bacterial expression clone containing a 6His-MBP-CBS fusion was
obtained from Macrolab at UC Berkeley (2C-T vector; http://www.
addgene.org/29706/). Substitutions within the CBS coding region were
then constructed using site-directed mutagenesis and conﬁrmed by
DNA sequencing, as was done with the yeast CBS expression con-
structs. MBP-CBS fusions were expressed in Rosetta 2 (DE3) cells
(Novagen; www.emdmillipore.com). Cells were grown in Luria broth
with 200 mg/mL ampicillin at 37 to an OD600 between 0.6 and 0.8,
and then the temperature was shifted to 20 and the cultures were
allowed to grow for an additional hour. Protein expression was then
induced by the addition of 1 mM IPTG (Gold Biotechnology, St.
Louis, MO) and either 0.3 or 0.6 mM d-ALA (Sigma-Aldrich, St.
Louis, MO) and the cells grown at 20 for an additional 15220 hr.
Cells were harvested by centrifugation and resuspended in 50 mL
of lysis buffer (50 mM Tris, pH 8; 300 mM NaCl; 0.5 mM TCEP; 50
mM pyridoxine-HCl; Sigma-Aldrich) with a cocktail of protease inhib-
itors (Roche Complete, EDTA-free). The cells were then lysed by
sonication, and the supernatant fraction collected by centrifugation.
Proteins were puriﬁed from the lysis supernatant using a Ni-NTA
afﬁnity resin (QIAGEN, Valencia, CA), eluted from the column in
lysis buffer with 250 mM imidazole, and then dialyzed into lysis buffer
to remove the imidazole and concentrate the puriﬁed protein. Protein
concentrations were determined by measuring the absorbance of the
aromatic side chains (Edelhoch 1967).
Absorbance spectra
Absorbance spectra were taken on puriﬁed proteins ranging in
concentration from 20 to 100 mM and then normalized to protein
concentration for comparison. The ratio of the heme 430 nm absorbance
peak and the aromatic 280 nm absorbance peak was one-to-one,
indicating nearly 100% heme incorporation in the major allele protein
(Majtan et al. 2010).
Proteolysis kinetics
Protease susceptibility of puriﬁed proteins was measured using
thermolysin. The puriﬁed protein sample was diluted to approxi-
mately 10 mM in lysis buffer. The reaction was initiated by the
addition of thermolysin at a ﬁnal concentration of 10 mg/mL at room
temperature. At deﬁned time intervals a portion of the reaction was
removed, and the protease digestion quenched by the addition of
ethylenediamine tetraacetic acid at a ﬁnal concentration of 12.5
mM. Samples were analyzed by 8% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis.
The MBP-CBS protein fusion, as well as the cleaved CBS and MBP
fragments, were excised from the gel and their identity conﬁrmed by
mass spectrometry by the following procedure. A nano LC column
packed with 10 cm of Polaris c18 5 mm packing material (Varian) was
loaded with the protein sample by use of a pressure bomb and washed
extensively with buffer A. The column was then directly coupled to an
electrospray ionization source mounted on a Thermo-Fisher LTQ XL
linear ion trap mass spectrometer. An Agilent 1200 HPLC equipped
with a split line, so as to deliver a ﬂow rate of 30 nL/min, was used for
chromatography. Peptides were eluted with a 90-min gradient from
100% buffer A to 60% buffer B. Buffer A was 5% acetonitrile/0.02%
heptaﬂurobutyric acid; buffer B was 80% acetonitrile/ 0.02% hepta-
ﬂurobutyric acid. The programs SEQUEST and DTASELECT were
used to identify peptides and proteins from a database consisting of
common contaminants and the engineered sequences of the proteins
(Eng et al. 1994; Tabb et al. 2002).
RESULTS
CBS-substitution yeast growth phenotypes
We used a cell-based assay to assess the impact of single amino acid
substitutions upon the function of the human CBS enzyme. A cDNA
clone of the major allele of the human CBS gene, or variant forms of
the gene, was expressed in S. cerevisiae and tested for functional com-
plementation of a null allele of the orthologous yeast gene, CYS4. This
strategy has several desirable qualities: (1) expression of the human
clone can be driven by a heterologous promoter and terminator so as
to minimize transcriptional effects on protein levels; (2) the expression
level of the complementing human clone can be modulated so as to
restore growth but remain limiting, thereby providing a sensitive assay
for both partial loss-of-function alleles or enhanced-function alleles; (3)
deﬁned growth media allow for the titration of exogenous pyridoxine
or bypass of CBS function entirely by the addition of cysteine in the
form of GSH to the growth medium; and (4) the yeast genome can be
engineered so as to alter other intermediates of the metabolic pathway.
This assay was used to rank order variant activities as well as vitamin,
or heme, responsiveness. We recently used this assay to catalog the
functional impact of the majority of CBS polymorphisms identiﬁed
clinically (Mayﬁeld et al. 2012).
The focus of this study was to examine the effect of single amino
acid substitutions on CBS function and the associated impact of
cofactor availability in a more direct fashion. Two strategies were used
degree of function are listed. Growth rates are expressed as a ratio relative to the yeast strain expressing the major human CBS allele, grown with the same amount of
exogenous pyridoxine supplementation (either 400, 4, 2, or 1 ng/mL pyridoxine), with the SD indicated (determined from at least three independent yeast trans-
formants). Growth rates that differed signiﬁcantly from the major allele in the same media conditions are indicated either by a single asterisk (P , 0.01) or a double
asterisk (P , 0.001). Growth rates that were not determined are indicated (n/d). CBS, cystathionine b-synthase.
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to construct a new collection of CBS variants, speciﬁcally trying to
enhance moderate functional impacts. The ﬁrst was a directed
strategy aimed at protein residues not directly involved in either
the binding of cofactor or the catalytic pocket, but dispersed
throughout the protein, that might result in a range of impacts on
protein function. The primary criteria were that the residue be (1)
buried within the hydrophobic core (i.e., no solvent accessibility),
and (2) distal from the PLP cofactor-binding site. Also, catalytic
residues were excluded because mutations of catalytic sites would
have clear deleterious effects independent of their effect on the free
energy of folding. We used Rosetta-based predictions of the ther-
modynamic impact of single amino acid substitutions as an ap-
proximate guide to be able to test a presumed range of destabilizing
mutations. The resulting set of 31 single amino-acid substitutions
was predicted to have a range of destabilizing impacts, from mild
to severe. The second strategy was random mutagenesis designed
to be unbiased with respect to protein residue and substitution
and resulted in another set of 27 single-amino-acid substitutions.
In total, 58 single amino acid substitutions were constructed in
the human CBS gene by these two strategies, and functionally
assayed in vivo. The complete list of substitutions and their predicted
impact on the thermodynamic stability of the protein based on the
Rosetta proﬁle is shown in Table 1.
The observed growth phenotypes were assigned to one of three
categories. The ﬁrst comprised those changes that failed to confer
growth even at the highest concentration of exogenous pyridoxine
supplementation (400 ng/mL). These 19 substitutions created a non-
functional enzyme as deﬁned by the in vivo growth assay. The remain-
ing two categories together comprised 39 substitutions that were able
to confer growth to some degree. Their in vivo activities were de-
termined at four concentrations of exogenous pyridoxine supplemen-
tation (Table 1). Twenty-ﬁve of these substitutions supported growth
rates comparable to wild type at all four concentrations of pyridoxine
supplementation, and were deﬁned as benign. The ﬁnal category of 14
substitutions conferred a growth rate that was signiﬁcantly different
from that of yeast with the major allele of human CBS in at least one
concentration of pyridoxine supplementation (pair-wise t test; P ,
.01). Although the majority of these substitutions exhibited slower
growth rates relative to wild type, particularly at low pyridoxine con-
centrations, three substitutions (I127V, I188V, and V371A) conferred
better growth than wild type. We refer to this category of 14 substi-
tutions as being cofactor sensitive.
Figure 2 Yeast in vivo growth complementation assay for human CBS function. (A) Scatter plot showing the predicted change in free energy
(Predicted DDG, x-axis) for 52 human single-amino-acid CBS substitutions vs. their conferred growth rates expressed relative to that of the major
human CBS allele grown with 400 ng/mL pyridoxine supplementation in HEM1 yeast strains (y-axis). The alleles were categorized by growth
phenotype as benign, sensitive, or nonfunctional (see Results). (B) Assessment of the calculated changes in free energy to predict the phenotypic
outcome for 52 human CBS substitutions. The alleles were binned based on the predicted change in free energy (DDG) in 0.5 kcal/mol incre-
ments. For each incremental threshold a percentage “correct” was calculated by summing the number of alleles growing below the threshold
added to the number of alleles not growing above the threshold, divided by the total number of alleles (i.e., 52). The dotted line indicates
a predicted DDG of 3.5 kcal/mol Rosetta units.
Figure 1 Positions of the altered CBS amino acid
residues on the 3D structure of the truncated CBS
protein. The pyridoxine and heme cofactors are shown
in black. (A) Forty-four amino acid residues representing
51 of the 58 substitutions are shown in red. Seven of the
substitutions were in residues not included in the 3D
structure and are not shown. (B) The fourteen residues
that, when substituted, resulted in CBS protein variants
with altered cofactor sensitivity in vivo. All variants dem-
onstrated altered sensitivity to pyridoxine; the two var-
iants that had altered sensitivity to both heme and
pyridoxine (K267E and L345P) are shown in green.
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The distributed nature of functional classes
of mutations
Some alleles led to proteins with decreased yet remediable function. For
these mutants, their loss or reduction in function could be compen-
sated by the binding of a cofactor. If the effect of these mutations on
the enzyme were local to the altered site, remediable alleles would
be expected to be close in structure to the cofactor-binding site. If,
however, the effect were more global, such as a general destabilization
of the protein, then remediable alleles may occur at a considerable
distance from the cofactor-binding site.
We used the structure of a truncated version of the major allele
protein as a framework for exploring the relative distribution of different
classes of variants. We mapped the positions of the 44 mutated residues
with positional information (representing 51 mutations, 7 mutations
were in residues not included in the solved structure) to examine if
there were any “hot spots” for the phenotypic categories (Figure 1).
There was no obvious clustering of any phenotypic classes to any
particular regions. Indeed, the mutated residues were located through-
out the structure and the different phenotypic categories were inter-
spersed. The lack of geographic bias added strength to the view that
the phenotypic categories were the result of distributed inﬂuences and
were not limited to region-speciﬁc properties.
To explore possible associations between physical characteristics of
substitutions and observed growth phenotype in a more quantitative
fashion, alleles were grouped based their growth phenotype: non-
functional, sensitive, or benign; each of these three groups were
further divided based on the method of molecular construction,
directed or random (six groups in all). For each category, ﬁve physical
characteristics were determined (distance between the substitution
and heme, distance between the substitution and PLP, solvent accessi-
bility, regular secondary structure, and crystal structure B-factor), and
category averages were calculated. For comparison, an equal number
of alleles were randomly assigned to each category 10,000 times and
category averages for the same ﬁve measurements performed allowing
a rigorous statistical test for the probability that the test category is
higher or lower than random.
As expected, the directed variants had signiﬁcantly less solvent
accessibility than the randomized controls because this was a criterion
in their selection. This correlation provided a positive control that the
analysis could detect correlations if they existed among the data.
Among the randomly generated variants, those with nonfunctional
or sensitive phenotypes were also less solvent accessible than either
the controls or the benign random substitutions. However, no other
physical parameter examined was characteristic of any of the pheno-
typic categories. The remediable alleles were no closer to either of the
cofactor binding sites, nor did they have altered occurrence in regular
secondary structure, or correlate with high or low crystallographic
B-factor values.
n Table 2 Growth Rates Supported by CBS Variants in a hem1D Background
Substituted
Residue
400 ng/mL B6 and 50 mg/mL
d-ALA
400 ng/mL B6 and 5 mg/ml
d-ALA
2 ng/mL B6 and 50 mg/ml
d-ALA
2 ng/mL B6 and 5 mg/mL
d-ALA
V118G 0.90 6 0.06 0.78 6 0.12 0.60 6 0.15 0.56 6 0.07
I142V 0.82 6 0.07 0.74 6 0.12 0.69 6 0.14 0.87 6 0.08
L181A 0.64 6 0.06 0.59 6 0.03 0.57 6 0.09 0.59 6 0.08
N225S 0.74 6 0.11 0.66 6 0.06 0.55 6 0.12 0.45 6 0.07
K267E 0.61 6 0.00 n/d 0.57 6 0.18 n/d
I286A 0.64 6 0.03 0.58 6 0.02 0.46 6 0.06 0.34 6 0.05
L293V 0.69 6 0.07 0.67 6 0.10 0.47 6 0.07 0.36 6 0.06
L345P 0.58 6 0.01 0.07 6 0.03 0.25 6 0.06 0.05 6 0.01
F385L 0.77 6 0.05 0.69 6 0.07 0.58 6 0.10 0.54 6 0.11
Relative growth rates of a subset of 9 B6-remediable single amino-acid human CBS substitutions expressed in yeast are listed. Each variant was grown in four media
conditions; 400 ng/mL pyridoxine and 50 mg/mL @-ALA, 400 ng/mL pyridoxine and 5 mg/mL @-ALA, 2 ng/mL pyridoxine and 50 mg/mL @-ALA, and 2 ng/mL
pyridoxine and 5 mg/mL @-ALA. As in Table 1, growth rates are expressed as a percentage relative to the yeast strain expressing the major allele of human CBS grown
with the same media. Averages were determined from at least three independent yeast transformants of each CBS variant. Conditions in which a variant was unable to
grow sufﬁciently to determine a growth rate are indicated (n/d). CBS, cystathionine b-synthase.
Figure 3 CBS variant growth rates at various levels of exogenous cofactor supplementation. (A) Growth rates for six variants grown with four levels
of pyridoxine supplementation (400, 4, 2, and 1 ng/mL) in HEM1 yeast strains. Growth rates are expressed relative to yeast with the major human
CBS allele grown with the same media conditions. (B) Growth rates for ﬁve of the same variants grown in hem1D strains, in either a high level of
pyridoxine (400 ng/mL, left panel) or a low level of pyridoxine (2 ng/mL, right). Additionally, these strains were grown with either high d-ALA
supplementation (50 mg/mL) or low d-ALA supplementation (5 mg/mL). The K267M variant was omitted because it did not show any sensitivity to
pyridoxine levels (A). All error bars indicate the standard deviation of at least three independent transformants.
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Correlations of thermodynamic predictions with
growth phenotypes
Although the Rosetta algorithm was used to select mutations with a
range of predicted effects on stability, the correlation between the
predicted effects on stability and observed effects on growth was
poor. The only reliable correlations were for those variants predicted
to be severely destabilizing (.4 kcal/mol on the Rosetta scale). Nine
of the 11 substitutions in this category resulted in a no-growth, no-
remediation phenotype (Figure 2A). The two remaining substitu-
tions (F385L and V354G) both were impaired and sensitive to low
levels of pyridoxine, in close agreement with a previous study (Wei
et al. 2010). Thus the 3.5- to 4-kcal/mole DDG prediction marked
a threshold above which all examined CBS variants were impaired,
and indeed most were completely nonfunctional (Figure 2B).
In contrast, the majority of mutations were predicted to cause
a more modest DDG effect and were selected precisely because of their
predicted intermediate effects on stability. These variants fell into all
three growth-phenotype categories (Figure 2A). There were no signif-
icant correlations between growth phenotype and the predicted
change in stability for mutations in this range of destabilization.
Characterization of cofactor remediation
Cofactor-remediable substitutions occurred at a signiﬁcant distance
from the binding site of that cofactor, which is consistent with the
hypothesis that the effects of remediable alleles were not local, and
were more likely a result of a modest destabilization of the protein. If
true, the cofactor sensitivity of a given variant may not be speciﬁc to
one cofactor. That is, interaction with a different cofactor, which also
binds at a distance from the substitution, may also provide enough
stabilization to at least partially compensate for the stability lost due to
the substitution. We examined this question by transforming the ﬁrst
nine B6-remediable alleles that we identiﬁed into a yeast hem1D strain
in which we could control the relative level of intracellular heme, the
other cofactor for CBS, by supplementing with either high or low
concentrations of d-amino levulinic acid (d-ALA). d-ALA is the prod-
uct of Hem1p and a precursor in heme biosynthesis (Table 2). Two
alleles, K267E and L345P, which were sensitive to low pyridoxine
levels, were also extremely sensitive to low d-ALA concentrations.
Neither of these substitutions was particularly close to either cofactor-
binding site; in fact L345P is on the opposite side of the monomer
from the heme-binding site (Figure 1). Therefore, these two alleles
encoded proteins that were severely impaired by low concentrations
of either cofactor, yet could be signiﬁcantly remediated by high con-
centrations of either.
Physical analysis of heme incorporation
To probe the nature of the remediable alleles, we focused on the
cofactor sensitivity of a subset of substitutions for in vitro analysis.
Considering that substitutions predicted to have changes in free en-
ergy less than 3.5 kcal/mol produced protein variants of all phenotypic
categories, we selected six variants for this analysis that were predicted
to have modest destabilizing effects, yet represented three of the phe-
notypic categories (the nonfunctional alleles were omitted). Of these,
two variants exhibited heightened sensitivities to levels of both cofac-
tors, pyridoxine and heme (K267E and L345P), an additional three
variants showed sensitivity to reduced pyridoxine levels but not heme
levels (L181A, I286A, and L293V), and the ﬁnal variant selected was
benign (K267M; Figure 3, A and B).
For the in vitro studies, the full-length CBS coding region was
fused to that of the maltose binding protein (MBP), which facilitated
the solubility of bacterially expressed CBS variants. To aid in the in-
tracellular production of heme and its subsequent incorporation into
the CBS protein during expression, the bacterial growth medium was
supplemented with d-ALA (Kery et al. 1994). This MBP-CBS fusion
protein was soluble when expressed in bacteria and could be readily
puriﬁed and assayed. The puriﬁcation yield varied signiﬁcantly among
the seven selected proteins (major allele and six variants) and corre-
lated with the intensity of a yellow/brown color of the puriﬁed protein
(Figure 4). This observation suggested that the amount of heme asso-
ciated with the puriﬁed variants also varied (Kery et al. 1994). Indeed,
the amount of protein-bound heme, measured spectrophotometrically,
varied signiﬁcantly among the protein variants and correlated with the
observed color (Figure 4A) and with activity in vivo as measured by
growth rate.
The observed differences in heme sensitivity in vivo and heme
incorporation in vitro suggested both that this collection of proteins
Figure 4 Heme content of puriﬁed variant CBS proteins. Photographs of cuvettes containing equal concentrations of each puriﬁed protein are
shown on the left. (A) Absorption spectra demonstrating the level of heme incorporation for seven CBS proteins. Bacterial cells expressing the
various CBS proteins were supplemented with 0.3 mM d-ALA in the growth medium. (B) Increased incorporation of heme for the CBS variants
when expressed with an increased concentration of exogenous d-ALA in the growth medium (0.3 mM [solid symbols] vs. 0.6 mM [open symbols]).
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varied in their ability to bind heme, and that changes in the availability
of heme inﬂuenced its incorporation, and subsequent enzymatic func-
tion. For example, K267E and L345P, which were most sensitive to
heme availability in vivo, incorporated the least heme, as measured
in vitro. Several of these variants, including the major allele, were ex-
pressed in cells grown at two concentrations of d-ALA, puriﬁed and
evaluated for heme incorporation (Figure 4B). Increased heme avail-
ability resulted in marginal gains in the low level of heme incorporated
into L345P and no detectable increase in K267E, consistent with the
extreme sensitivity of these two variants to lowered levels of heme. In
contrast, L293V, I286A and the major allele form of CBS had more
associated heme under these conditions, presumably reﬂecting a
greater fraction of CBS molecules that had incorporated heme, and
supported greater growth.
Physical analysis of protein stability
One method to interrogate the stability and dynamics of a puriﬁed
protein is to examine its sensitivity to proteases (Park and Marqusee
2006). The differences in in vivo function, heme content in the puri-
ﬁed proteins, and their altered sensitivity to pyridoxine levels collec-
tively implied that the alleles described in Figure 4 likely resulted
in a conformational perturbation of the protein. Therefore, we
examined their relative sensitivity to thermolysin cleavage. The
thermolysin-sensitivity of the major allele full-length CBS and variants
has been used previously to detect whether substitutions affected the
conformational stability for other variants of CBS (Hnizda et al. 2012a).
Under the conditions used here, the MBP fragment was quickly
cleaved from the full-length CBS domain, even at the lowest protease
levels tested. The remaining full-length major-allele CBS remained
largely resistant to further degradation by thermolysin treatment for
20 min (Figure 5). Longer protease time points eventually degraded
the full-length CBS (not shown). The sensitivity to thermolysin di-
gestion varied signiﬁcantly among the alleles. Importantly, the degree
of sensitivity correlated with heme content. The less heme incorpo-
rated in the protein, the more sensitive the CBS variant was to pro-
tease digestion (Figure 6). These results implied that heme-binding
stabilized the protein to proteolysis.
DISCUSSION
In this study we interrogated the relationship between protein structure
and cofactor-level sensitivity of mutant variants of human CBS, a B6-
dependent enzyme with a key role in metabolism. Importantly, cofactor-
remediable variants occurred at positions dispersed throughout the
structure of the protein. The dually remediable variants, responsive to
both B6 and heme cofactors, were striking in that the changes in these
variants were not proximal to the binding site of either cofactor. The dual
B6- and heme-level sensitivities of two variants in particular raised the
possibility that iron deﬁciency, or other contributions to heme function,
might also impact enzyme function in humans carrying these alleles.
Five of the six single amino acid substitutions of CBS selected for
physical analysis exhibited altered sensitivity to the B6 cofactor in vivo
(the sixth, functionally benign K267M variant, was included in this set
as a control), but displayed differing phenotypes with respect to heme-
level sensitivity. Three variants, (L181A, I286A, and L293V) exhibited
sensitivity to reduced pyridoxine levels relative to the major allele, but
no heightened sensitivity to reduced heme levels based upon growth-
rate measurements. However, there was a range of heme incorporation
among these alleles in vitro. The L181A variant appeared to incorporate
a level of heme similar to the protein encoded by the major allele,
although the other two CBS variants incorporated less heme. These
variants established that heightened B6-level sensitivity was not nec-
essarily coupled with discernable effects on heme loading or confor-
mational stability, and suggested that there may be a threshold with
respect to heme loading and protein function in vivo.
Perhaps the most interesting alleles were those that encode K267E
and L345P, which exhibited the most extreme in vivo sensitivity to
reduced levels of either pyridoxine or heme. Upon puriﬁcation both
variant proteins bound far less heme than wild-type CBS, and ex-
hibited the most enhanced thermolysin sensitivity of the seven CBS
versions tested. Heme incorporation into CBS protein appears to be
obligatorily co-translational, and reduced heme binding in turn affects
PLP binding (Kery et al. 1994; Oliveriusova et al. 2002). Thus variants
with reduced heme binding would be expected to alter PLP binding
and yield a protein with reduced function, as was observed for these
two alleles. But at a ﬁxed level of heme availability, and presumably
therefore at a ﬁxed level of heme incorporation, these two variants also
showed altered activity to pyridoxine concentrations in vivo. It would
appear that variants with heightened sensitivity to the levels of two
cofactors commonly have heightened conformational ﬂexibility, as
measured by protease sensitivity, relative to variants with more spe-
ciﬁc sensitivities.
Taken to a logical conclusion, these striking examples raise the
possibility that a small molecule ligand that binds to one position of
a protein can suppress the impact of a destabilizing mutation at
a distant site. This notion is consistent with the observation that the
physical impacts of a number of clinical CBS alleles result in subtle
alterations of protein structure (Hnizda et al. 2012b) and that small
molecule chaperones can rescue function (Kopecka et al. 2011; Majtan
et al. 2010). If so, small molecules that restore function to variant
proteins could have signiﬁcant translational importance. Moreover,
there is growing recognition of cryptic binding sites for small mole-
cules that are obscured in crystal structures but revealed in molecular
dynamic simulations (Bowman and Geissler 2012).
Clearly, experimental evaluation of all amino acid substitutions in
the human proteome would be technically daunting. Hence robust
computational prediction of the impact of variation would be desirable
if personalized medicine is to reach its full potential. However, the
results described here demonstrate that single amino acid substitutions
that are calculated to have a modest impact on protein stability can
nevertheless impact protein function, ranging from nonfunctional to
benign. The needed improvements in predictive methods rely on
datasets that interrogate the impact of many alleles of a protein. The 58
alleles of CBS described here, combined with previous studies, offer an
increasingly useful resource for such developments.
Figure 5 Protease digestion of the puriﬁed major allele MBP-CBS
fusion protein. After treatment with thermolysin for the indicated time
(minutes), the digested protein is separated by polyacrylamide gel
electrophoresis. The full-length CBS protein (with MBP removed) runs
as a doublet; the identities of all of the labeled bands were conﬁrmed
by Mass-Spectrometry analysis. Iota marks the lane with no protease.
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